TransCode Therapeutics, Inc. has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int'l (Holdings) Inc. to fund its lead microRNA candidate, TTX-MC138, through a Phase 2 clinical trial.
The acquisition represents a strategic expansion of TransCode's oncology pipeline, combining Polynoma's advanced melanoma vaccine with TransCode's proprietary RNA therapeutics platform. Philippe Calais, PharmD, PhD, who was appointed Chief Executive Officer following the announcement, stated that this move allows the company to create a unique and broader oncology pipeline with Phase 3-ready seviprotimut-L and the TTX-MC138 program. These combined assets position TransCode to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
This development is significant for cancer patients and the oncology field because it brings together two promising therapeutic approaches at critical stages of development. Seviprotimut-L represents a late-stage vaccine candidate specifically targeting stage IIB and IIC melanoma, a form of skin cancer that has spread regionally but not yet distantly. The vaccine's polyvalent shed antigen approach could provide a new treatment option for patients who have undergone surgical removal of their melanoma but remain at high risk of recurrence.
Meanwhile, the $25 million investment from CK Life Sciences ensures continued development of TTX-MC138, TransCode's lead therapeutic candidate focused on treating metastatic tumors that overexpress microRNA-10b. This biomarker represents a unique, well-documented indicator of metastasis, making TTX-MC138 potentially applicable across multiple cancer types where metastasis occurs. The funding will specifically support the program through Phase 2 clinical trials, bringing the treatment closer to potential regulatory approval and patient access.
The combination of these assets creates a comprehensive approach to cancer treatment, addressing both localized advanced disease through the melanoma vaccine and systemic metastatic disease through the RNA therapeutic platform. For investors and the pharmaceutical industry, this transaction demonstrates continued interest and investment in innovative cancer treatments, particularly those targeting specific biomarkers and utilizing novel delivery mechanisms. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
TransCode's proprietary TTX nanoparticle platform represents an important advancement in RNA therapeutics delivery, potentially overcoming historical challenges that have limited the clinical application of RNA-based treatments. The company's portfolio includes other first-in-class RNA therapeutic candidates designed to unlock therapeutic access to various novel genetic targets relevant to treating multiple cancers. This acquisition and funding arrangement accelerates the development timeline for both programs, potentially bringing new treatment options to cancer patients sooner while demonstrating the viability of combining traditional vaccine approaches with cutting-edge RNA therapeutics in oncology drug development.
